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Abstract
The human gastrointestinal tract harbours a complex microbial community which exist in planktonic and sessile form. The
degree to which composition and function of faecal and mucosal microbiota differ remains unclear. We describe the
development and characterisation of an in vitro human gut model, which can be used to facilitate the formation and
longitudinal analysis of mature mixed species biofilms. This enables the investigation of the role of biofilms in Clostridium
difficile infection (CDI). A well established and validated human gut model of simulated CDI was adapted to incorporate
glass rods that create a solid-gaseous-liquid interface for biofilm formation. The continuous chemostat model was
inoculated with a pooled human faecal emulsion and controlled to mimic colonic conditions in vivo. Planktonic and sessile
bacterial populations were enumerated for up to 46 days. Biofilm consistently formed macroscopic structures on all glass
rods over extended periods of time, providing a framework to sample and analyse biofilm structures independently. Whilst
variation in biofilm biomass is evident between rods, populations of sessile bacterial groups (log10 cfu/g of biofilm) remain
relatively consistent between rods at each sampling point. All bacterial groups enumerated within the planktonic
communities were also present within biofilm structures. The planktonic mode of growth of C. difficile and gut microbiota
closely reflected observations within the original gut model. However, distinct differences were observed in the behaviour
of sessile and planktonic C. difficile populations, with C. difficile spores preferentially persisting within biofilm structures. The
redesigned biofilm chemostat model has been validated for reproducible and consistent formation of mixed species
intestinal biofilms. This model can be utilised for the analysis of sessile mixed species communities longitudinally,
potentially providing information of the role of biofilms in CDI.
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Introduction
The human colon is a highly complex and diverse ecosystem
lined by a mucous membrane. Bacterial populations within the
gastrointestinal tract exist in two forms; planktonic free-floating
communities within the lumen, and sessile bacteria within
mucosal-associated biofilm communities. The mucus layer protects
the underlying epithelium from the external environment,
including pathogens [1]. The microorganisms present in the
gastrointestinal tract often form multispecies sessile communities
attached to the mucosal layer [2,3]. Mucosal communities interact
closely with host epithelial cells, and thereby may have a greater
influence than planktonic populations on disease pathogenesis and
immunomodulatory responses. Despite these potential important
roles, many intestinal microbiota studies are derived from faecal
samples and only provide information on planktonic populations.
Mucosal populations are difficult to investigate in healthy
individuals due to the physical inaccessibility of the gut; thus,
there has been restricted study of these communities. The degree
to which composition and function of faecal and mucosal
microbiota differ remains unclear, although some reports suggest
distinct differences in microbial composition at the two sites [3,4].
The use of in vitro models of the gastrointestinal tract have been
used to model planktonic and sessile communities [5–7], but
typically over short time frames.
C. difficile infection (CDI) is a major threat in hospital and long-
term care facilities worldwide and associated with significant
financial burden [8]. Recurrence of disease symptoms is a
particular challenge [9,10]. Perturbation of the normal gut
microflora (e.g. by antibiotic therapy) is the main risk factor for
CDI [11,12]. However, as the sessile intestinal microbiota
populations are not well studied, the role of biofilms in CDI and
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recurrence is poorly understood. Biofilms have been implicated in
chronic disease [13], and so may well be an important factor in
recurrence of CDI.
In order to investigate long-term changes in intestinal micro-
biota, for example following antimicrobial therapy or in CDI
development, more temporally robust models are required. We
describe the development and characterisation of an in vitro
continuous chemostat human gut model that facilitates the
formation of mature mixed species biofilms, which can be
longitudinally harvested and analysed separately. This chemostat
system was validated for the consistent formation of 18 indepen-
dent rod-associated biofilm structures, in both single- and triple-
stage gut model systems.
Methods
In vitro human gut model
We have previously described the use of a triple-stage chemostat
human gut model to study the interaction between antimicrobial
agents, the indigenous gut microbiota and C. difficile [14–16]. This
model has been validated against physicochemical and microbi-
ological measurements from the intestinal contents of sudden
death victims[17], and comprises three pH-maintained
(pH 5.560.2, vessel 1; pH 6.260.2, vessel 2 and pH 6.860.2,
vessel 3) fermentation vessels connected in a weir cascade
formation. The model is sparged with nitrogen and top-fed with
a complex growth medium at a controlled rate (D= 0.015 h21).
Constituents and preparation of growth medium for the gut model
are as described previously [14]. The gut model was inoculated
with a faecal emulsion (,10% w/v in pre-reduced PBS) prepared
from C. difficile-negative faeces of three healthy elderly ($60 yrs)
volunteers with no history of antimicrobial therapy for at least 3
months.
Biofilm human gut model
This original model was adapted to facilitate the formation of
macroscopic, mixed species biofilm by utilising a redesigned
biofilm vessel. Eighteen glass rods were inserted into the vessel
through the lid and positioned to ensure the sampling portion of
the rod extended across the liquid/gas interface. Rods were
screwed into the lid system and anaerobic atmosphere maintained
Figure 1. Experimental designs used in this study. Experimental design of (a) single stage (model A1 and A2) and (b) triple stage biofilm gut
model validation experiments (models B1 and B2). Vertical line represents the last day of each time period. CD, C. difficile PCR ribotype 027 spores.
doi:10.1371/journal.pone.0088396.g001
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by the delivery of nitrogen gas to the vessel via a circular pipe, with
drilled holes interspersed on the surface to encourage even
distribution of gas flow across the rods.
Ethics Statement
The only ethical consideration necessary for the use of an in vitro
gut model is for the collection and use of faecal donations from
adult volunteers. This approval was provided from the Leeds
Institute of Health Sciences and Leeds Institute of Genetics,
Health and Therapeutics and Leeds Institute of Molecular
Medicine, University of Leeds joint ethics committee (reference
HSLTLM/12/061). Donors were provided with a participant
information sheet, clearly outlining requirements and use of
samples, and stating that by providing the sample to the
researcher, participants were consenting for that sample to be
used in research involving the in vitro gut model. To preserve
anonymity of participants, no written consent was recorded. The
need for written informed consent from the participants was
waived by the University of Leeds joint ethics committee.
Experimental design
Model A1 and A2. Duplicate single-stage gut model valida-
tion experiments (figure 1A).
The redesigned biofilm model was assembled as a single stage
vessel only that was top fed with growth medium. Nine ground/
roughened and nine smooth glass rods were incorporated. Pooled
human faecal emulsion was added to the vessel, the media pump
was started and the system was left without intervention to allow
bacterial populations to equilibrate for 31 days (period A, figure1
A). On day 31 a single inoculum of C. difficile PCR ribotype 027
spores (,107 cfu) were added to the vessel (period B). The model
was left without interventions until day 46 when all 18 rods were
removed from the model for analysis. Planktonic indigenous gut
microbiota (periods A–C), C. difficile total viable counts, spores and
cytotoxin (periods B and C) were determined at regular intervals
for the duration of the experiment. The experiment was
performed twice to determine reproducibility of results.
Model B1 and B2. Duplicate triple-stage gut model valida-
tion experiments (figure 1B).
A more complex redesigned biofilm model comprising three
vessels was assembled. Eighteen ground/roughened rods were
inserted into the biofilm vessel, situated in vessel 3. Pooled human
faecal emulsion was added to all three vessels, the media pump
started, and the system was left without intervention for 19 days
(figure 1B, period A). On day 20, rods 1–6 (sample point Z) were
selected from all areas of the vessel, removed, and bacterial
populations enumerated. A single inoculum of C. difficile PCR
ribotype 027 spores (,107 cfu) were added to vessel 1 of the model
on day 21 and the system was left without further interventions
until rods 7–12 (sample point Y) were sampled on day 27. The
remaining rods were sampled on day 42 (sample point W).
Planktonic indigenous gut microbiota (periods A–C, vessels 2 and
3), C. difficile total viable counts, spores and cytotoxin (periods B
and C, vessels 1–3) were monitored during the experiment. The
experiment was performed twice to assess reproducibility.
Enumeration of gut microbiota and C. difficile total viable
counts, spores and cytotoxin
Planktonic and biofilm-associated gut microbiota populations
cultured were: total facultative anaerobes, total anaerobes
(facultative + obligate), lactose fermenting Enterobacteriaceae, entero-
cocci, lactobacilli, bifidobacteria, total Clostridium spp., Bacteroides
fragilis group, C. difficile total viable counts (vegetative C. difficile +
spores) and C. difficile spore viable counts. C. difficile toxin
production was monitored using a Vero cell cytotoxicity assay as
described previously [18]. Planktonic cultures were serially diluted
in pre-reduced peptone water to 1027. Twenty microliters of four
appropriate dilutions were inoculated to quarter plates of each
culture medium in triplicate and incubated anaerobically (obligate
anaerobes) or aerobically (facultative anaerobes) at 37uC for
48 hours. Colonies were identified to genus level on the basis of
colony morphology, Gram reaction and microscopic appearance
on selective and non selective agars (table 1).
Biofilm –associated bacterial populations were enumerated
following careful removal of rods from the biofilm model. Rods
were transferred into 5 mL pre-reduced saline, thoroughly
vortexed for ,2 mins and the rod discarded. Re-suspended
biofilm was centrifuged at 4000 rpm for 10 mins, the supernatant
was then removed and re-suspended in 2 mL pre-reduced saline.
Table 1. Culture medium used for the isolation and enumeration of indigenous gut microbiota and C. difficile (all agar bases are
supplied by Oxoid, with the exception of CCEYL and FAA supplied by LabM, and made according to the manufacturer’s
instructions).
Medium Target species
Fastidious anaerobe agar (FAA) supplemented with 5% horse blood Total anaerobes and total clostridia
Bacteroides Bile Aesculin agar (BBE) supplemented with 5 mg/L haemin, 10 mL/L vitamin K, 7.5 mg/L vancomycin,
1 mg/L penicillin G, 75 mg/L kanamycin, 10 mg/L colisitin
B. fragilis group.
LAMVAB agar: 52.5 mg/L MRS broth, 20 mg/L agar technical supplemented with 0.5 g/L cysteine HCl, 20 mg/L
vancomycin, adjusted to pH 5
Lactobacillus spp.
Beerens agar: 42.5 mg/L Columbia agar, 5 mg/L agar technical supplemented with 5 mg/L glucose, 0.5 g/L cysteine
HCl, 5 mL propionic acid, adjusted to pH5
Bifidobacterium spp.
Nutrient agar Total facultative anaerobes
MacConkey agar Lactose-fermenting Enterobacteriaceae
Kanamycin Aesculin Azide agar supplemented with 10 mg/L nalidixic acid, 10 mg/L aztreonam, 20 mg/L kanamycin Enterococcus spp.
Alcohol shock followed by Brazier’s CCEY agar supplemented with 2% lysed horse blood, 5 mg/L lysozyme, 256
mg/L cycloserine, 8 mg/L cefoxitin
C. difficile spores
Brazier’s CCEYL agar as described above supplemented with 2 mg/L moxifloxacin C. difficile total viable counts
doi:10.1371/journal.pone.0088396.t001
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A 500 mL aliquot was centrifuged and stored at 4uC for cytotoxin
assay as previously described [18]. The remaining biofilm
suspension was enumerated as described above and units were
reported as log10 cfu/g of biofilm.
Results
Models A1 and A2
All rods facilitated the growth of biofilm within the single stage
gut model. The macroscopic biofilm mass differed amongst rods
Figure 2. Sessile bacterial populations in models A1 and A2. Mean (6SE) rod-associated populations (log10 cfu/g) of indigenous gut
microbiota within the single stage biofilm gut model (a-model A1; b-model A2). Each point represents the populations present on a single rod. B.
fragilis group – below limit of detection (,3 log10 cfu/g). LFE – Lactose-fermenting Enterobacteriaceae.
doi:10.1371/journal.pone.0088396.g002
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with total pellet weight ranging from 0.034 to 0.122 g with an
average (6SE) weight of 0.06860.007 g in model A1, and 0.021
to 0.082 g with an average (6SE) weight of 0.04660.004 g in
model A2. In general there was no correlation between biofilm
biomass and rod position, or rod surface topography (smooth or
roughened/ground) between different experiments. This indicates
that, although there are differences in biofilm biomass, these are
not due to microenvironments within the vessel).
Planktonic gut microbiota
The majority of indigenous gut microbiota in both models A1
and A2 established a steady population, with the exception of B.
fragilis group, which declined to below the limit of detection in
model A1 and was only sporadically detected at low levels (,2–5
log10 cfu/mL) during period A in model A2 (data not shown).
Sessile gut microbiota
Sessile communities of all enumerated bacterial groups, except
B. fragilis group were present on the glass rods (figure 2). Within
model A1, Lactobacillus spp. dominated biofilm populations (mean
9.88 log10 cfu/g), whilst Bifidobacterium spp. (mean 9.18 log10 cfu/
g) dominated sessile populations within model A2. Enterococcus spp.
(mean 5.03 and 5.16 log10 cfu/g in model A1 and A2, respectively)
was the least abundant bacterial group in both models. The
relative proportions of each bacterial group were similar in
planktonic and sessile form, although planktonic population counts
were generally greater than their sessile counterparts.
Variation between sessile bacterial populations across all rods in
each experiment (model A1 and A2) was minimal (table 2), with
standard errors (SE) of variation of most bacterial groups #0.18
log10 cfu/g. Enterococcus spp. demonstrated greatest variation
within model A1 (0.3 log10 cfu/g). Within model A1, Enterococcus
spp. population variation between rods 1–12 (SE 60.05 log10 cfu/
g) was minimal and comparable to that of other bacterial groups.
However, increased variation was evident on rods 13–17 (SE
60.57 log10 cfu/g), a trend not observed for other bacterial groups
on these particular rods. Variation of this bacterial group in model
A2 was comparable to that of other bacterial groups.
Planktonic and sessile C. difficile
C. difficile spores were instilled into the vessel on day 31 and
remained in spore form for the duration of the experiment in both
models. Planktonic populations declined to the limit of detection
by the final day of the experiment (data not shown). C. difficile were
detected in spore form within rod-associated biofilms on the final
day of the experiment, with sessile populations up to 3 log10 cfu/g
greater than their planktonic counterparts.
Models B1 and B2
Planktonic gut microbiota. Vessel 3 was the only biofilm
vessel, and so is of most relevance for validation against planktonic
populations; therefore, only indigenous gut microbiota results from
vessel 3 are reported here. Planktonic indigenous gut microbiota
rapidly established a stable population, and remained predomi-
nantly steady for the duration of the experiment (data not shown).
Instillation of C. difficile spores (day 21, period B) did not
substantially affect microbiota populations.
Sessile gut microbiota. Bacterial group populations across
the 6 rods sampled at each time point displayed minimal variation,
with standard errors of #0.35 log10 cfu/g at all time points
(table 3). Biofilm communities were dominated by lactose-
fermenting Enterobacteriaceae, with Enterococcus spp. the least
numerous bacterial group for all time points (figures 3 & 4).
Rod-associated populations for each bacterial group remained
largely steady across the 3 time points, although Clostridium spp., B.
fragilis group and Bifidobacterium spp. populations reduced modestly
at time point X (,1–2 log10 cfu/g decline). Variations (SE) of
sessile populations at time point X were generally more
pronounced compared with previous time points.
Planktonic C. difficile. C. difficile populations initially
remained quiescent in all vessels of the gut model (data not
shown). However, ,5 days after C. difficile spore instillation, TVCs
began to increase by ,1–2 log10 cfu/mL relative to spore
populations and maintained this level for the duration of the
experiment. C. difficile spore populations decreased from peak
levels of 4.5 log10 cfu/mL to ,3 log10 cfu/mL by the end of the
experiment. Cytotoxin was not detected throughout the experi-
ment in model B1, but was observed (2RU) on the penultimate day
of the experiment in model B2 (data not shown).
Sessile C. difficile. Following C. difficile spore instillation
(day 21; post time point Z), C. difficile populations existed solely as
Table 2. Mean and standard error values (log10 cfu/g) of sessile and planktonic populations of indigenous gut microbiota and C.
difficile on rods 1–17 in models A1 and A2. TVC – total viable counts; NR – no result, LOD – limit of detection.
Bacterial group Mean sessile (log10 cfu/g)
Standard error of sessile counts
(log10 cfu/g) Mean planktonic (log10 cfu/g)
Model A1 Model A2 Model A1 Model A2 Model A1 Model A2
Facultative anaerobes 8.66 8.99 0.07 0.02 9.51 10.40
Lactose-fermenting Enterobacteriaceae 6.42 8.96 0.11 0.15 6.62 10.39
Enterococcus spp. 5.03 5.16 0.30 0.13 4.70 5.83
Total anaerobes 9.44 10.03 0.06 0.10 10.92 11.35
Clostridium spp. 7.59 8.07 0.09 0.16 9.23 NR
Bifidobacterium spp. 8.61 9.18 0.06 0.10 10.81 10.09
B. fragilis gp. ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD
Lactobacillus spp. 9.88 8.73 0.10 0.11 10.40 9.32
C. difficile TVC 3.74 4.97 0.18 0.14 ,LOD ,LOD
C. difficile spores 4.19 6.20 0.11 0.11 3.45 3.20
doi:10.1371/journal.pone.0088396.t002
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spores, with no indication of vegetative cell presence within all rod-
associated biofilm structures at time points X and Y in models B1
and B2 (figures 5a and b). C. difficile spores were present within
biofilm structures (mean TVCs 5.51–6.62 log10 cfu/g), 6 days after
spore introduction into the model (time point Y, figures 5a and b).
C. difficile populations existed in spore form only, with little
population variation amongst rods (standard error: TVCs and
spores 0.13–19 log10 cfu/g, table 3). On the final day of the
experiment (day 46, time point X), mean sessile C. difficile spores
had declined to 4.83 and 5.53 log10 cfu/g in models B1 and B2,
respectively (time point X, figures 5a and b). Variation (SE) of C.
difficile populations amongst rods at time point X was greater than
Figure 3. Bacterial populations in model B1. Mean (6 SE) rod-associated populations (log10 cfu/g) of (a) facultative (b) obligate anaerobes
within the triple stage biofilm gut model (model B1) at time points Z- X. Planktonic populations of each bacterial group (log10 cfu/g) at each time
point are represented by a line. LFE – lactose-fermenting Enterobacteriaceae.
doi:10.1371/journal.pone.0088396.g003
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other bacterial groups with TVC and spore standard errors of
0.12–0.4 log10 cfu/g.
Discussion
A well established, validated in vitro human gut model of
simulated C. difficile infection has been adapted to incorporate a
rod system to facilitate the independent formation and analysis of
18 rod-associated multi-species biofilms, thus allowing longitudinal
Figure 4. Bacterial populations in model B2. Mean (6 SE) rod-associated populations (log10 cfu/g) of (a) facultative (b) obligate anaerobes
within the triple stage biofilm gut model (model B2) at time points Z- X. Planktonic populations of each bacterial group (log10 cfu/g) at each time
point are represented by a line. LFE – lactose-fermenting Enterobacteriaceae.
doi:10.1371/journal.pone.0088396.g004
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analysis of composition over weeks or months. In order to allow
future work comparing biofilm composition at different time
points, and under different conditions, the consistency of biofilm
formation and composition across all rods, regardless of position
within the vessel was validated. The validation process was initially
carried out within a single stage model (i.e. the biofilm vessel only)
and later in a triple stage system where vessel 3, representing the
distal colon, was replaced with the biofilm vessel. These
experiments were performed in duplicate and demonstrate the
high level of reproducibility of the model. Due to the time and
labour intensive nature of this model the practicality of numerous
repeat experiments is limited. The measurement of planktonic
populations within this model has previously been validated and
repeated on numerous occasions, with high level of reproducibility
observed [19–22]. Further work with the biofilm model would
provide increased confidence in the reproducibility of sessile
populations but were beyond the limits of this project.
The biofilm gut model provides a reproducible system in which
to study the growth of mature, multi-species biofilm. Maximal
biofilm formation was macroscopically evident at the liquid/gas
interface on each rod, with a plaque-like biofilm growth on
submerged areas. Attempts were made to ensure a homogenous
environment for biofilm formation; however, some variation in
biofilm biomass was evident across the 18 rods, although no
relationship between rod position and biofilm biomass was
evident. Microenvironments within the model were evident, with
variations in fluid turbidity likely due to gas flow. Shear forces and
turbidity levels within a fluid regulate biofilm formation, with
turbid environments eliciting increased biofilm formation [23],
potentially explaining the biomass variation observed within this
study. Roughened and smooth glass rods were utilised in models
A1/2. Despite reports of surface topography affecting biofilm
formation [24,25], no evidence of variation in biofilm mass or
composition were evident in this study. Previous reports focus on
the differences in early bacterial colonisation rates on different
materials [25,26], a parameter not investigated within this study.
However, robustness of biofilm structures on roughened rods was
greater than those on smooth glass rods.
The triple stage experimental design (models B1 and B2)
facilitated the investigation of sessile communities at 3 distinct time
points, with rod-associated biofilm biomass generally decreasing as
the experiment progressed. The biofilm lifecycle is a dynamic
process and variation in biofilm biomass identified at these distinct
time points may be a result of individual rod-associated biofilms
existing at difference stages. Biofilm detachment is regulated by
factors such as pH, nutrient availability and sheer forces [23,27],
and therefore decreased mass may be due to communities
reaching increased structural stability and optimal biomass at
different stages in the experiment.
Despite vessel design alteration compared with the original gut
model, planktonic indigenous gut microbiota and C. difficile
populations within the biofilm vessel of all models (A1/2 and
B1/2) closely reflected observations in previous gut model
experiments [14,28]. Slight variation (average, 0.7 log10 cfu/g;
maximum 2.5 log10 cfu/g) in planktonic indigenous gut microbi-
ota populations was evident between repeating experiments
(models A1/2 and models B1/2), potentially caused by inter-
and intra-bacterial variation in donor stools [4]. B. fragilis group
populations were detected sporadically at low levels within the
planktonic cultures of the single stage models, as observed
previously within the gut model [29]. Detection of Bacteroides
spp. within distinct regions of the colon of sudden death victims
are variable [30]. Reasons behind these differences are unclear,
but may be mediated by the reduced pH, increased substrate
availability in vessel 1 (proximal) compared to vessel 3 (distal) and
resulting unique fermentation profiles within different regions of
the model [17].
Sessile bacterial group populations (log10 cfu/g) remained
consistent across rods within each experiment and results from
the single (models A1 and A2) and triple (model B1 and B2) stage
models were reproducible. All bacterial groups isolated from the
planktonic mode of growth were also present within the rod-
associated biofilms, with the exception of B. fragilis group within
the single stage models, correlating with the absence or low levels
of this group within the planktonic culture.
In order to compare planktonic and sessile populations from a
single time point, populations from both modes of growth were
expressed as log10 cfu/g. In general, planktonic indigenous gut
microbiota populations were higher than their sessile counterparts,
as observed by Macfarlane et al [6], but not Probert and Gibson
[31]. The weight of the pellet from a 1 mL suspension of
planktonic culture fluid or re-suspended biofilm was used to
determine the cfu per gram of biomass. Planktonic cultures are
likely to contain a high proportion of bacteria within this biomass,
Table 3. Mean (log10 cfu/g) and standard error (SE) of rod-associated populations of indigenous gut microbiota at sample points
Z, Y and X in the triple stage biofilm gut model B1 and B2. NR – no result.
Bacterial group Sessile mean ±SE Sample point Z
Sessile mean
± SE Sample point Y Sessile mean ± SE Sample point X
B1 B2 B1 B2 B1 B2
Facultative anaerobes 9.71 (60.07) 9.22 (60.06) 9.22 (60.20) 9.80 (60.15) 9.60 (60.08) 9.61 (60.09)
Lactose-fermenting Enterobacteriaceae 9.70 (60.11) 9.10 (60.05) 9.57 (60.14) 9.80 (60.15) 9.49 (60.09) 9.54 (60.17)
Enterococcus spp. 7.94 (60.30) 6.36 (60.34) 7.57 (60.09) 6.75 (60.33) NR 6.34 (60.35)
Total anaerobes 9.48 (60.06) 9.87 (60.02) 10.32 (6.006) 10.21 (60.15) 9.51 (60.10) 9.72 (60.11)
Clostridium spp. 7.82 (60.09) 8.24 (60.09) 9.27 (60.15) 8.37 (60.09) 6.72 (60.28) 6.24 (60.07)
Bifidobacterium spp. 8.29 (60.06) 8.46 (60.04) 9.07 (60.15) 7.97 (60.13) 7.79 (60.18) 7.26 (60.30)
B. fragilis gp. 7.97 (60.24) 7.87 (60.08) 8.82 (60.17) 8.58 (60.05) 7.27 (60.31) 7.38 (60.28)
Lactobacillus spp. 8.03 60.10 7.87 60.08 8.49 60.12 7.42 60.18 7.52 60.14 6.81 60.26
C. difficile TVC NR NR 6.19 60.13 5.38 60.13 4.49 60.40 4.79 60.14
C. difficile spores NR NR 6.62 60.19 5.51 60.14 5.53 60.28 4.83 60.12
doi:10.1371/journal.pone.0088396.t003
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whilst biofilm is comprised of a large amount of extracellular
material in addition to the bacterial mass, possibly explaining this
observation [32]. Sessile facultative anaerobic populations, partic-
ularly Enterococcus spp. were generally higher than planktonic
populations. The lower ratio of anaerobes to aerobes at the gut
mucosal surface compared with the lumen has previously been
observed in vivo [4] and in vitro [6]. An increased level of variation
in Enterococcus spp. populations relative to other bacterial groups
was observed within these experiments, particularly model A1.
Within model A1, green pigmentation, presumptively identified as
Figure 5. C. difficile populations in models B1 and B2. Mean (6 SE) rod-associated populations (log10 cfu/g) of C. difficile within the triple stage
biofilm gut model (model B1 – a; model B2 - b) at time points Z- X. Planktonic C. difficile populations (log10 cfu/g) at each time point are represented
by a line.
doi:10.1371/journal.pone.0088396.g005
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pseudomonal growth was observed in biofilms on rods associated
within increased Enterococcus spp. variation (rods 13–17, model A1).
The association of P. aeruginosa with E. faecalis has previously been
noted [33], potentially implying a symbiotic relationship between
the two organisms. The presence of P. aeruginosa may lead to
recruitment of increased levels of enterococci species into biofilm
structures.
Within the original gut model an internal control period was
designed to demonstrate the quiescent nature of C. difficile spores in
the absence of antimicrobial intervention. During this period
within models B1 and B2, planktonic C. difficile TVCs increased
relative to spore levels, demonstrating the presence of low levels
(,1–2 log10 cfu/mL) of planktonic C. difficile vegetative/active
cells within the model. Whilst germination of C. difficile spores
appeared evident, proliferation of vegetative cells remained
restricted, particularly in model B1. Persistence of planktonic C.
difficile spore populations (i.e. washout absence), whilst unusual, has
previously been observed within the original gut model [34,35].
Whilst the presence of increased TVCs compared with spores was
evident within planktonic C. difficile communities, there was no
evidence of this trait within biofilm populations. Biofilm formation
and sporulation pathways are interconnected and differentially
regulated by the master regulator Spo0A in Bacillus. subtilis [36]. C.
difficile possesses a Spo0A orthologue with 56% amino acid
homology to that of B. subtilis. This orthologue plays a key role in
C. difficile sporulation and biofilm formation [37,38]. The C. difficile
biofilm lifecycle is a complex process, which remains to be fully
elucidated. Sessile bacteria possess distinct metabolic and pheno-
typic characteristics from their planktonic counterparts, including
reduced growth rate. The recruitment of quiescent spores into a
dormancy-inducing biofilm structure enhances the likelihood of
spores remaining inactive. C. difficile spores germinate in response
to external stimuli such as pH, heat and nutrients such as glycine
and taurocholate [39–41]. Conditions within planktonic fluid of
the human gut model may vary markedly from the protected
environment of biofilms, potentially eliciting the diverse behaviour
of C. difficile between the two phases. Results presented here
demonstrate the planktonic and biofilm modes of growth of C.
difficile PCR ribotype 027 only. Despite reduction in the
prevalence of this ribotype within the UK, [42] it is still clinically
relevant in many parts of the world and is associated with poor
outcomes[43,44]. Inter-strain spore coat heterogeneity is thought
to exist within C. difficile, and may confer a greater adherence
capability for certain strains. The further use of the biofilm gut
model to investigate the association of different PCR ribotypes to
biofilm structures may provide useful additional information on
inter-strain heterogeneity and any potential clinical relevance.
The preferential persistence of C. difficile spores in the biofilm
phase described here offers both a reinforcement of the need to
examine planktonic and sessile populations and a tantalising
suggestion that biofilms could play a key role in CDI recrudes-
cence. Therapeutic options that can address C. difficile spore
persistence, notably in biofilms, may have clinical advantage, for
example in terms of reduced propensity for disease relapse.
The biofilm chemostat gut model has been validated for
reproducible and consistent formation of mixed species intestinal
biofilms. This model can be utilised for the analysis of sessile mixed
species communities longitudinally, potentially providing further
information on the persistence of C. difficile spores within biofilms
and the role this may play in recurrent CDI. In particular, this
could offer new insights into the efficacy of novel therapeutics for
CDI.
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